Loading…
iBio, Inc. is projected to rise to $2.26 by 2027, a +20% move from its current price of $1.88. IBIO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.79 | $1.88 | $1.97 | +0.02% |
| May 30 | $1.76 | $1.88 | $2.01 | +0.04% |
| May 31 | $1.73 | $1.88 | $2.04 | +0.06% |
| Jun 1 | $1.71 | $1.88 | $2.07 | +0.08% |
| Jun 2 | $1.69 | $1.88 | $2.09 | +0.11% |
| Jun 3 | $1.68 | $1.88 | $2.11 | +0.13% |
| Jun 4 | $1.66 | $1.88 | $2.13 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.66 | $1.88 | $2.13 | +0.15% |
| Week 2 | $1.58 | $1.89 | $2.25 | +0.29% |
| Week 3 | $1.52 | $1.89 | $2.34 | +0.44% |
| Week 4 | $1.48 | $1.89 | $2.42 | +0.59% |
| Week 5 | $1.44 | $1.89 | $2.50 | +0.74% |
| Week 6 | $1.40 | $1.90 | $2.57 | +0.89% |
| Week 7 | $1.37 | $1.90 | $2.64 | +1.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
iBio, Inc. is a healthcare company focused on the development of artificial intelligence antibody solutions for the cardiometabolic and obesity space. The company operates in the preclinical biotechnology space and pursues platforms and pipelines intended to improve antibody performance and targeting.
Its technology platforms include EngageTx that provides an improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies toward desired regions of target proteins.
Its product pipelines for the cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhances the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and a TROP-2 x CD3 bispecific antibody developed with the EngageTx platform to harness T cells to kill TROP-2‑expressing tumors while minimizing cytokine release. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases.
The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
iBio, Inc. (IBIO) operates in the healthcare sector as a biotechnology company focused on AI-driven antibody solutions for cardiometabolic diseases and obesity. The stock trades with a current price of $1.84 and a market capitalization of $91.41M, and it holds a rank of 4279.
The long-run outlook is reflected in a year-by-year forecast that envisions gradual price appreciation across several years, with substantial upside in the later years. The forecast includes a wide range of potential outcomes, from a flat 2026 path to multifold gains by 2050, with max values reaching into the double digits in some years.
A major floor 40.8% below — a decisive break under it would weaken the trend.
The nearest floor, 24.5% below — buyers have tended to step in here.
The nearest ceiling, 12.2% above — a clean break opens room to run.
A major ceiling 63.3% above — clearing it would confirm fresh momentum.
Key IBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.83 | Buy | $1.80 | Buy |
| MA 10 | $1.66 | Buy | $1.74 | Buy |
| MA 20 | $1.66 | Buy | $1.73 | Buy |
| MA 50 | $1.87 | Buy | $1.85 | Buy |
| MA 100 | $2.13 | Sell | $1.90 | Sell |
| MA 200 | $1.64 | Buy | $1.87 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.26 | Neutral |
| Stoch RSI (14) | 96.50 | Sell |
| CCI (20) | 141.13 | Buy |
| Williams %R (14) | -2.13 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 9.94 | Buy |
| Bollinger %B (20,2) | 0.93 | Neutral |
| Stochastic %K (14) | 97.87 | Sell |
| TRIX (15) | -0.68 | Sell |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 68.63 | Neutral |
| Momentum (10) | 0.27 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 1.95 | Sell |
| ADX (14) | 19.31 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is described as BULLISH. The RSI(14) is 50, and the short- to intermediate-term moving averages sit at SMA50 of $1.89 and SMA200 of $1.63, framing a constructive baseline for price action. Key support is located at $1.42 and resistance at $2.20, providing a defined trading range over the near term.
Over the last 30 days, the stock has traded within a range from $1.33 to $2.55, indicating notable volatility within a relatively tight parameter.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.42 | $1.88 | $2.69 | 0% | Neutral | |
| $1.67 | $2.26 | $3.30 | +20% | Bullish | |
| $2.22 | $3.17 | $4.90 | +69% | Bullish | |
| $2.22 | $3.31 | $5.34 | +76% | Bullish | |
| $2.39 | $3.70 | $6.19 | +97% | Bullish | |
| $2.39 | $3.84 | $6.62 | +104% | Bullish | |
| $1.88 | $3.13 | $5.55 | +66% | Bullish | |
| $2.33 | $4.00 | $7.27 | +113% | Bullish | |
| $3.04 | $5.40 | $10.04 | +187% | Bullish | |
| $3.06 | $5.61 | $10.66 | +198% | Bullish | |
| $3.61 | $7.68 | $15.92 | +308% | Bullish | |
| $5.51 | $12.24 | $28.14 | +551% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.42 | $1.88 | $2.22 | +0.00% |
| June 2026 | $1.60 | $1.91 | $2.36 | +1.68% |
| July 2026 | $1.58 | $1.92 | $2.42 | +0.25% |
| August 2026 | $1.47 | $1.80 | $2.30 | -6.31% |
| September 2026 | $1.47 | $1.81 | $2.36 | +0.94% |
| October 2026 | $1.59 | $1.98 | $2.61 | +9.27% |
| November 2026 | $1.61 | $2.02 | $2.69 | +2.09% |
| December 2026 | $1.58 | $2.00 | $2.69 | -1.11% |
Click any year to see its month-by-month IBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IBIO price prediction for 2026 points to an average of $1.88 (low $1.42, high $2.69) — a potential gain of 0% on today's $1.88. Price action looks broadly range-bound.
In 2027, IBIO is projected to trade between $1.67 and $3.30, averaging $2.26 — a potential gain of +20% from today's $1.88. That is up +20% on the projected 2026 average. Buyers look set to stay in control over this stretch.
iBio, Inc.'s 2028 outlook centres on $3.17, within a $2.22 to $4.90 range. That is up +41% on the projected 2027 average. That marks a +69% change versus current levels. Momentum favours further upside here.
By 2029, IBIO could reach as high as $5.34, with a base case around $3.31 and support toward $2.22 — roughly +76% from $1.88. Buyers look set to stay in control over this stretch.
Expect IBIO to range from $2.39 to $6.19 through 2030. The $3.70 average target implies a +97% move from current prices. That is up +12% on the projected 2029 average. Momentum favours further upside here.
The IBIO price prediction for 2031 points to an average of $3.84 (low $2.39, high $6.62) — a potential gain of +104% on today's $1.88. Buyers look set to stay in control over this stretch.
In 2032, IBIO is projected to trade between $1.88 and $5.55, averaging $3.13 — a potential gain of +66% from today's $1.88. That is -19% versus the projected 2031 average. Momentum favours further upside here.
iBio, Inc.'s 2033 outlook centres on $4.00, within a $2.33 to $7.27 range. That is up +28% on the projected 2032 average. That marks a +113% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, IBIO could reach as high as $10.04, with a base case around $5.40 and support toward $3.04 — roughly +187% from $1.88. Momentum favours further upside here.
Expect IBIO to range from $3.06 to $10.66 through 2035. The $5.61 average target implies a +198% move from current prices. That is up +4% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The IBIO price prediction for 2040 points to an average of $7.68 (low $3.61, high $15.92) — a potential gain of +308% on today's $1.88. Momentum favours further upside here.
In 2050, IBIO is projected to trade between $5.51 and $28.14, averaging $12.24 — a potential gain of +551% from today's $1.88. That is up +59% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IBIO today (≈ 531.914894 IBIO) could be worth
$6,508.22
+$5,508.22 (+551%) by 2050 · US Dollar
Based on the average projected IBIO price of $12.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IBIOwould be worth at today's price.
$1,000 invested in IBIO on May 27, 2025 (≈ 1,234.567898 IBIO) would be worth
$2,320.99
+$1,320.99 (+132.1%) today · 2.32× · US Dollar
Based on a IBIO entry price of $0.81 vs. today's $1.88.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.7 | $1,105.88 | +10.6% |
| 1 month ago | $1.71 | $1,099.42 | +9.9% |
| 3 months ago | $3.07 | $612.38 | -38.8% |
| 6 months ago | $1.23 | $1,528.46 | +52.8% |
| 1 year ago | $0.81 | $2,320.99 | +132.1% |
| All time (5.0y) ago | $740 | $2.54 | -99.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IBIO forecast.
Our base-case forecast reaches $3.80 around 2031.
Implied market cap at $3.80: $188.78M
The multi-year forecast shows meaningful upside over time. In 2030 the average price is projected to be $3.42 with a max of $5.81 and a min of $2.16, for a reported ROI of 85.6% in that year. The trajectory continues with a 2040 average of $6.29 (max $13.33, min $2.83) and a 241.6% ROI, followed by 2050 with an average of $10.04 (max $23.10, min $4.52) and a 445.8% ROI.
The 2026 forecast begins at an average of $1.84 (max $2.62, min $1.42) with a 0% ROI, and 2027–2033 show continued growth with substantial gains in several years, including 2028 (avg $2.90, ROI 57.5%), 2029 (avg $3.07, ROI 66.7%), 2031 (avg $3.44, ROI 86.9%), 2034 (avg $4.64, ROI 152%), and 2035 (avg $4.86, ROI 163.9%). The long-run figures imply upside potential but are defined as estimates rather than guarantees. Investors should consider the inherent uncertainty and market factors that can influence outcomes.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.42 with a max of $5.81 and a min of $2.16, and an ROI of 85.6%.
The forecast indicates potential upside with a sequence of rising averages (e.g., 2027 avg $2.11; 2028 avg $2.90; 2029 avg $3.07; 2030 avg $3.42) and rising ROI (peaking at 85.6% in 2030, 241.6% in 2040, 445.8% in 2050). However, the earliest year shows no gain (2026 avg $1.84, ROI 0%), and forecasts are not guarantees.
Yes. The 2050 forecast presents an average price of $10.04 with a max of $23.10 and a min of $4.52, accompanied by an ROI of 445.8%.
IBIO’s current price is $1.84 per share with a market cap of $91.41M and a rank of 4279.
For 2040, the forecast shows an average price of $6.29 with a min of $2.83 and a max of $13.33, and an ROI of 241.6%.
iBio, Inc. Community Discussion
0Share your iBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.